Lilly Endowment (LLY) plans 300,000-share Eli Lilly common stock sale
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Lilly Endowment Inc. has filed a notice of proposed sale under Rule 144 to sell 300,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets. The filing reports an aggregate market value of 322,944,000 for these shares, with an approximate sale date of 12/23/2025 and 945,383,757 Eli Lilly shares outstanding.
The notice also lists prior sales of Eli Lilly common stock by Lilly Endowment over the past three months, including 300,000 shares sold on 11/03/2025 for gross proceeds of 266,648,940 and several other large transactions in late September, October, and November 2025. By signing, the seller represents that it is not aware of any material adverse, nonpublic information about Eli Lilly’s operations.
Positive
- None.
Negative
- None.
FAQ
What does Lilly Endowment’s Rule 144 notice mean for Eli Lilly (LLY)?
The notice states that Lilly Endowment Inc. plans to sell 300,000 shares of Eli Lilly and Company common stock under Rule 144. This is a planned sale of existing shares and does not involve Eli Lilly issuing new stock.
What prior Eli Lilly (LLY) stock sales by Lilly Endowment are disclosed?
The notice details multiple past 3‑month sales of Eli Lilly common stock by Lilly Endowment, including 113,694 shares on 09/30/2025, 351,015 shares on 10/01/2025, and 300,000 shares on 11/03/2025 with gross proceeds of 266,648,940, among other listed transactions.
What representation does the seller make about Eli Lilly’s nonpublic information?
By signing the notice, the seller represents that it does not know any material adverse information about Eli Lilly’s current or prospective operations that has not been publicly disclosed.